TABLE 3.
Detection rates in different SEPT9 and BMP3 methylation cutoff values.
| SEPT9 methylation–Cutoffs | |||||
|---|---|---|---|---|---|
| 0.84 (AA + CRC) | 2.50 (CRC) | ||||
| Negative (%) | Positive (%) | Negative (%) | Positive (%) | ||
| Lesion a (n = 247) | |||||
| Control a | 42 | 25 (59.5) | 17 (40.5) | 38 (90.5) | 4 (9.5) |
| Adenomas | |||||
| NAA | 113 | 48 (42.5) | 65 (57.5) | 95 (84.1) | 18 (15.9) |
| AA | 44 | 21 (47.7) | 23 (52.3) | 37 (84.0) | 7 (16.0) |
| Serrated Polyp | |||||
| HP | 12 | 7 (58.3) | 5 (41.7) | 12 (100.0) | 0 (0.0) |
| Cancer | 36 | 12 (33.4) | 24 (66.6) | 17 (47.3) | 19 (52.7) |
| Stage (n = 36) | |||||
| I | 9 | 5 (55.6) | 4 (44.4) | 7 (77.8) | 2 (22.2) |
| II | 8 | 3 (37.5) | 5 (62.5) | 4 (50.0) | 4(50.0) |
| III | 13 | 5 (38.5) | 8 (61.5) | 7 (53.8) | 6 (46.2) |
| IV | 6 | 0 (0.0) | 6 (100.0) | 0 (0.0) | 6 (100.0) |
| BMP3 methylation–Cutoffs | |||||
|---|---|---|---|---|---|
| 0.16 (AA + CR) | 2.30 (CRC) | ||||
| Negative (%) | Positive (%) | Negative (%) | Positive (%) | ||
| Lesion a (n = 244) | |||||
| Control a | 42 | 26 (61.9) | 16 (38.1) | 37 (88.1) | 5 (11.9) |
| Adenomas | |||||
| NAA | 110 | 60 (54.5) | 50 (45.5) | 90 (81.8) | 20 (18.2) |
| AA | 45 | 24 (53.3) | 21 (46.7) | 39 (86.7) | 6 (13.3) |
| Serrated Polyp | |||||
| HP | 12 | 8 (66.7) | 4 (33.3) | 11 (91.7) | 1 (8.3) |
| Cancer | 35 | 20 (57.1) | 15 (42.9) | 22 (62.9) | 13 (37.1) |
| Stage (n = 35) | |||||
| I | 9 | 4 (44.4) | 5 (55.6) | 4 (44.4) | 5 (55.6) |
| II | 8 | 6 (75.0) | 2 (25.0) | 7 (87.5) | 1 (12.5) |
| III | 12 | 9 (75.0) | 3 (25.0) | 9 (75.0) | 3 (25.0) |
| IV | 6 | 1 (16.7%) | 5 (83.3) | 2 (33.3) | 4 (66.7) |
Note: Chi‐squared test was used to calculate p value.
Abbreviations: AA, advanced adenoma; CRC, colorectal cancer; HP, hyperplastic polyp; NAA, nonadvanced adenoma.
a
Samples with no significant lesion identified on the colonoscopy.